{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"PD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Number of participants who completed at least 2 treatment cycles with evidence of response. Response is defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression","groups":[{"description":"Subjects who completed at least 2 cycles of treatment with temsirolimus dose of 20 mg/m\\^2 or 27 mg/m\\^2 were assessed for radiologic response.","id":"OG000","title":"Temsirolimus 20 mg/m^2 and 27 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only participants who completed at least 2 treatment cycles (14/18 participants) were included to assess this outcome measure.","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}